Table 5 Drugs targeting validated KDTs with the potential to revert RP effects, highlighting functionally studied promising drug repositioning candidates
Gene | Drug name | DrugBank ID | Pharmacological action |
|---|---|---|---|
ALOX5 (240) | Sulfasalazine | DB00795 | Inhibitor |
ALOX5 (240) | Diethylcarbamazine | DB00711 | Inhibitor |
ALOX5 (240) | Mesalazine | DB00244 | Inhibitor |
ALOX5 (240) | Balsalazide | DB01014 | Inhibitor |
ALOX5 (240) | Masoprocola | DB00179 | Inhibitor |
ALOX5 (240) | Meclofenamic acid | DB00939 | Inhibitor |
ELOVL4 (6785) | Omega-3-carboxylic acids | DB09568 | Potentiator |
GABRA1 (2554) | Methohexital | DB00474 | Antagonist |
GABRA1 (2554) | Flumazenil | DB01205 | Antagonist |
GLRA2 (2742) | Taurine | DB01956 | Agonist |
GRIN1 (2902) | Orphenadrine | DB01173 | Antagonist |
SLC12A5 (57468) | Bumetanide | DB00887 | Inhibitor |